The Weekly Roundup: Counseling for Travel Health (5.24.19)

May 24, 2019 | Pamela Youngberg

Repercussions from the U.S. measles outbreak continue to emerge. The latest victim: air travel, as officials leverage the CDC’s Do Not Board list as a deterrent against the spread of disease. As the summer travel season heats up, there is a range of considerations pharmacists can counsel patients on with the aim of increasing the likelihood of a healthy journey. In addition to proper vaccination, there is advice for avoiding insect-related illnesses and suggestions for an international first-aid kit. For certain patients, like your diabetes patients, there are specific recommendations. (There are special tips for those traveling by air here.)

Continue reading →

The Weekly Roundup: Skin Cancer Awareness (5.17.19)

May 17, 2019 | Pamela Youngberg

Skin cancer is on the rise, especially in Arizona, Colorado, and on the eastern seaboard. May is Skin Cancer Awareness Month, and it is a great time to increase conversations about sun protection—even in our Sterling pharmacies in Minnesota, where theoretically the last of the snow has come and gone (fingers crossed). Pharmacists have played a historic role in prevention and continue to do so today. These products are among those that your patients are reading about in the consumer press. Here are some tips for making sun protection recommendations in advance of Memorial Day Weekend. Consider sharing stories like this across your social feeds to raise awareness of the condition. Or, feel free to download or share this free resource to supplement your patient education.

Continue reading →

The Weekly Roundup: Pet Meds and Your Pharmacy (5.10.19)

May 10, 2019

There is little doubt that for most pet owners, Fido is part of the family—and may represent a good way to diversify pharmacy topline revenue. Popular retailer PetSmart launched an online pet pharmacy in 2017, and this week, Walmart got on board with their own launch of an online pet pharmacy. It also announced a plan to expand its existing roster of store-based pet vet clinics from 21 to 100 over the next year. The market is ripe—especially among certain demographics—who want options for buying their pet meds. Despite cautions around purchasing Fido’s medications online, as shared by this New Hampshire-based vet clinic, pulling people into the pharmacy for pet meds won’t be easy, but it’s been a boon for this independent. If you are looking to add pet care to your lineup, check out these ideas for stepping into the market.

Continue reading →

The Weekly Roundup: Measles Outbreak Breaking Records (5.3.19)

May 03, 2019 | Pamela Youngberg

This week, Merck announced it was responding to an uptick in demand for the measles vaccine during the largest outbreak in a quarter century. From January to April 26 this year, the CDC reports 704 cases have been confirmed in 22 states. Offshore, a cruise ship has been quarantined after a confirmed case of measles was reported, with broad exposure among passengers feared. A 2015 New York bill to drop religious exemptions for vaccinations is stalled despite the area being one of the heaviest hit by the outbreak.

Continue reading →

The Weekly Roundup: Rules of Attraction (4.26.19)

April 27, 2019 | Pamela Youngberg

“Often staying successful is about learning and changing rather than sticking to the tried-and-true.” —Dane Holmes, Head of Human Capital Management, Goldman Sachs

This week, AARP and McDonald’s announced a program to help fill a quarter of a million seasonal jobs and a pilot program designed to match low-income seniors with jobs. When Goldman Sachs faced a recruiting crisis, it took two key steps to make sure it was reaching the best talent available: It widened the funnel to capture a broader range of applicants and identified the key competencies required to succeed at the firm, then stuck to structured questions to get at those competencies.

Continue reading →

The Weekly Roundup: Insulin May Be the Canary in the Coal Mine (4.19.19)

April 19, 2019 | Pamela Youngberg

A subcommittee of the House Energy and Commerce Committee heard testimony earlier this month on the human toll of rising insulin costs as a case study to better understand the impact on patients on prescription pricing overall. According to Rep. Brett Guthrie (R-KY 2nd District), “The prescription drug supply chain is complex, and it lacks transparency. There is limited public information around drug prices due to a lack of transparency around rebates and other price concessions.” The Kaiser Family Foundation recently reported that total Medicare Part D spending on insulin increased by 840% between 2007 and 2017, with no generics available and Eli Lilly, Novo Nordisk, and Sanofi dominating the market. In Minnesota, Attorney General Lori Swanson sued the three. While common wisdom (and massive advertising dollars spent by the Big Pharma lobby) justify high prices as attributable to the cost of R&D, rising insulin costs—which have been averaging 10 percent annually—may go a long way toward putting that argument to bed.

Continue reading →

The Weekly Roundup: Pharmacists & Pain Management (3.29.19)

March 29, 2019 | Pamela Youngberg

In the midst of an opioid crisis—and where substance abuse is in the headlines nearly every day—treating patients’ pain is a considerable challenge. In the case of cancer patients, for example, opioids remain the go-to, but there are additional approaches available, including drug therapies that change the mind’s perception of pain or those that block the pain signal from traveling to the brain. Researchers are also exploring gene therapies and approaches that juice the feel-good chemicals in the body.

There has been a groundswell of support for pharmacists to get more involved in managing pain treatment plans, buoyed by stories of both positive outcomes and unhappy endings.

Continue reading →

The Weekly Roundup: Expanding Naloxone Access (3.15.19)

March 15, 2019 | Pamela Youngberg

In a close vote, an advisory panel has recommended that practitioners co-prescribe naloxone with opioid prescriptions, and the recommendation is currently under review by the FDA. Health and Human Services has echoed the recommendation, providing guidance to prescribe naloxone for individuals at risk of opioid overdose, “including, but not limited to: individuals who are on relatively high doses of opioids, take other medications which enhance opioid complications or have underlying health conditions.” Proponents have suggested the recommendation could promote a healthy dialogue between providers and patients. However, detractors like Mary Ellen McCann, associate professor of anesthesia at Harvard Medical School, think the measure is too expensive—and potentially ineffective.

Continue reading →